Insulin-like growth factor pathway-targeted therapy in breast cancer

Saad Kenderian, Paul Haluska

Research output: Contribution to journalArticle

Abstract

The insulin-like growth factor (IGF) pathway plays an important role in cancer development, survival, metastasis, and resistance to antineoplastic therapies in various malignancies. Components of the IGF pathway are potential targets for novel anticancer therapy. In breast cancer, preclinical and clinical data suggest that IGF signaling is critical for tumor growth and resistance to therapy, leading to poor prognosis. There is also evidence of cross-talk between IGF, estrogen, erbB, and mTOR pathways; a potential mechanism of cancer resistance to hormonal or HER2-targeted therapy. This review discusses the rationale and strategies being evaluated in the clinical development of targeting the IGF pathway. It highlights the potential interactions between the IGF pathway and other therapies in breast cancer, and also focuses on the completed and ongoing clinical trials of different IGF pathway-targeted therapies in breast cancer.

Original languageEnglish (US)
Pages (from-to)6-14
Number of pages9
JournalCurrent Breast Cancer Reports
Volume3
Issue number1
DOIs
StatePublished - Mar 2011

Fingerprint

Somatomedins
Breast Neoplasms
Therapeutics
Neoplasms
Antineoplastic Agents
Estrogens
Clinical Trials
Neoplasm Metastasis
Growth

Keywords

  • Antibodies
  • Clinical trials as
  • IGF Type 1
  • Monoclonal
  • Protein kinase inhibitors
  • Receptor

ASJC Scopus subject areas

  • Oncology

Cite this

Insulin-like growth factor pathway-targeted therapy in breast cancer. / Kenderian, Saad; Haluska, Paul.

In: Current Breast Cancer Reports, Vol. 3, No. 1, 03.2011, p. 6-14.

Research output: Contribution to journalArticle

@article{c069e6f6a3ab4b02a1f85253fe285bce,
title = "Insulin-like growth factor pathway-targeted therapy in breast cancer",
abstract = "The insulin-like growth factor (IGF) pathway plays an important role in cancer development, survival, metastasis, and resistance to antineoplastic therapies in various malignancies. Components of the IGF pathway are potential targets for novel anticancer therapy. In breast cancer, preclinical and clinical data suggest that IGF signaling is critical for tumor growth and resistance to therapy, leading to poor prognosis. There is also evidence of cross-talk between IGF, estrogen, erbB, and mTOR pathways; a potential mechanism of cancer resistance to hormonal or HER2-targeted therapy. This review discusses the rationale and strategies being evaluated in the clinical development of targeting the IGF pathway. It highlights the potential interactions between the IGF pathway and other therapies in breast cancer, and also focuses on the completed and ongoing clinical trials of different IGF pathway-targeted therapies in breast cancer.",
keywords = "Antibodies, Clinical trials as, IGF Type 1, Monoclonal, Protein kinase inhibitors, Receptor",
author = "Saad Kenderian and Paul Haluska",
year = "2011",
month = "3",
doi = "10.1007/s12609-010-0030-4",
language = "English (US)",
volume = "3",
pages = "6--14",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Insulin-like growth factor pathway-targeted therapy in breast cancer

AU - Kenderian, Saad

AU - Haluska, Paul

PY - 2011/3

Y1 - 2011/3

N2 - The insulin-like growth factor (IGF) pathway plays an important role in cancer development, survival, metastasis, and resistance to antineoplastic therapies in various malignancies. Components of the IGF pathway are potential targets for novel anticancer therapy. In breast cancer, preclinical and clinical data suggest that IGF signaling is critical for tumor growth and resistance to therapy, leading to poor prognosis. There is also evidence of cross-talk between IGF, estrogen, erbB, and mTOR pathways; a potential mechanism of cancer resistance to hormonal or HER2-targeted therapy. This review discusses the rationale and strategies being evaluated in the clinical development of targeting the IGF pathway. It highlights the potential interactions between the IGF pathway and other therapies in breast cancer, and also focuses on the completed and ongoing clinical trials of different IGF pathway-targeted therapies in breast cancer.

AB - The insulin-like growth factor (IGF) pathway plays an important role in cancer development, survival, metastasis, and resistance to antineoplastic therapies in various malignancies. Components of the IGF pathway are potential targets for novel anticancer therapy. In breast cancer, preclinical and clinical data suggest that IGF signaling is critical for tumor growth and resistance to therapy, leading to poor prognosis. There is also evidence of cross-talk between IGF, estrogen, erbB, and mTOR pathways; a potential mechanism of cancer resistance to hormonal or HER2-targeted therapy. This review discusses the rationale and strategies being evaluated in the clinical development of targeting the IGF pathway. It highlights the potential interactions between the IGF pathway and other therapies in breast cancer, and also focuses on the completed and ongoing clinical trials of different IGF pathway-targeted therapies in breast cancer.

KW - Antibodies

KW - Clinical trials as

KW - IGF Type 1

KW - Monoclonal

KW - Protein kinase inhibitors

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=79951813624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951813624&partnerID=8YFLogxK

U2 - 10.1007/s12609-010-0030-4

DO - 10.1007/s12609-010-0030-4

M3 - Article

VL - 3

SP - 6

EP - 14

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 1

ER -